DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

An Open-Label Phase II Study of Nivolumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 2

Active, not recruiting

Conditions: Meningiomas

Interventions: Drug: Ipilimumab - 1 mg/kg
Drug: Nivolumab - 240 mg
Drug: Nivolumab - 480 mg
Drug: Nivolumab - 3 mg/kg
Radiation: External Beam RT

First Posted Date: 2016-01-07

Last Posted Date: 2024-12-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT02648997

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Improving Surgical Decision-making in Young Women With Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Other: qualitative data collection
Other: survey
Other: decision aid

First Posted Date: 2015-12-31

Last Posted Date: 2020-06-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 145

Registration Number: NCT02644382

Gut Decontamination In Pediatric Allogeneic Hematopoietic

Phase 2

Completed

Conditions: Hematopoietic Stem Cell Transplantation (HSCT)
Acute GVH Disease

Interventions: Drug: Vancomycin-polymyxin B

First Posted Date: 2015-12-29

Last Posted Date: 2023-09-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT02641236

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Novel Social Media Intervention For Older Br CA Patients

Not Applicable

Completed

Conditions: Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage III

Interventions: Other: PatientsLikeMe (PLM)

First Posted Date: 2015-12-24

Last Posted Date: 2021-08-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 47

Registration Number: NCT02639208

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Phase 2

Active, not recruiting

Conditions: Inflammatory Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions: Drug: Eribulin
Drug: Adriamycin
Drug: Cyclophosphamide

First Posted Date: 2015-12-08

Last Posted Date: 2024-02-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT02623972

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Ibrutinib

First Posted Date: 2015-11-13

Last Posted Date: 2022-12-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT02604511

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Phase 1

Terminated

Conditions: Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos
Rhabdoid Tumor
Rhabdomyosarcoma
Wilms Tumor
Clear Cell Renal Cell Carcinoma
Renal Tumor
Sarcoma
Soft Tissue Sarcoma
Sarcoma, Ewing
Ewing Sarcoma

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2015-10-21

Last Posted Date: 2021-04-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02581384

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Obinutuzumab
Drug: Ibrutinib

First Posted Date: 2015-09-01

Last Posted Date: 2024-07-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT02537613

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

A Study of Lenalidomide for Adult Histiocyte Disorders

Phase 2

Active, not recruiting

Conditions: Langerhans Cell Histiocytosis (LCH)
Histiocytoses Erdheim-chester Disease
Histiocytic Sarcoma (HS)

Interventions: Drug: Lenalidomide

First Posted Date: 2015-08-14

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT02523040

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Active, not recruiting

Conditions: Pediatric Solid Tumor

Interventions: Genetic: Genetic testing and GAIN report

First Posted Date: 2015-08-13

Last Posted Date: 2024-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 825

Registration Number: NCT02520713

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy